Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R M Hay

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 13, 2015
In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiencyG N Pike, A M Cumming, C R M Hay, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 26, 2014
A national survey of immunosuppression strategies for acquired haemophilia AP Batty, B Palmer, E Chalmers, et al.
Thrombosis Research|January 4, 2011
EUHASS: The European Haemophilia Safety Surveillance systemM Makris, G Calizzani, K Fischer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 11, 2014
The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparisonC R M Hay, B P Palmer, E A Chalmers, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 20, 2017
Efficacy and safety of Nuwiq<sup>®</sup> (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical proceduresN Zozulya, C M Kessler, A Klukowska, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99S C Darby, D M Keeling, R J D Spooner, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophiliaR A Gruppo, D Malan, J Kapocsi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 17, 2004
Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' OrganizationK J Pasi, P W Collins, D M Keeling, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 24, 2017
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patientsP W Collins, D V K Quon, M Makris, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 25, 2006
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conferenceE Berntorp, A Shapiro, J Astermark, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 13, 2015
In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiencyG N Pike, A M Cumming, C R M Hay, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 26, 2014
A national survey of immunosuppression strategies for acquired haemophilia AP Batty, B Palmer, E Chalmers, et al.
Thrombosis Research|January 4, 2011
EUHASS: The European Haemophilia Safety Surveillance systemM Makris, G Calizzani, K Fischer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 11, 2014
The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparisonC R M Hay, B P Palmer, E A Chalmers, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 20, 2017
Efficacy and safety of Nuwiq<sup>®</sup> (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical proceduresN Zozulya, C M Kessler, A Klukowska, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99S C Darby, D M Keeling, R J D Spooner, et al.
Journal of Thrombosis and Haemostasis : JTH|August 29, 2018
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophiliaR A Gruppo, D Malan, J Kapocsi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 17, 2004
Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' OrganizationK J Pasi, P W Collins, D M Keeling, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 24, 2017
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patientsP W Collins, D V K Quon, M Makris, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 25, 2006
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conferenceE Berntorp, A Shapiro, J Astermark, et al.
Pageof 4